10-Q quarterly report · filed Nov 4, 2026

AtriCure, Inc. (ATRC) Q3 2026 10-Q Quarterly Report

Short answer

AtriCure, Inc. (ATRC) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $154M (up 15.0% year over year) with net income of $4M.

Q3 2026 key financials · XBRL

Revenue
$154M
+15.0% YoY · +0.6% QoQ
Net income
$4M
+1622.1% YoY · −54.6% QoQ
Operating margin
2.8%
Gross margin
77.3%
EPS (diluted)
$0.09
+1000.0% YoY · −50.0% QoQ

Source: XBRL data from the AtriCure, Inc. (ATRC) Q3 2026 10-Q on SEC EDGAR. USD.

AtriCure, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $154,450, up 15.0% YoY from $134,269
  • Gross margin 77.3% vs 75.5% YoY, operating margin 2.8% vs 0.2%
  • Best line: pain management $28,057, up 34.6%; worst: minimally invasive ablation $5,389, down 27.5%
  • Cash and equivalents $187,031, debt $61,000, unused borrowing capacity $62,750
  • Outlook: 30 mm AtriClip FLEX-Mini launch expected before year-end 2026, competition and PFA adoption headwinds

Risk Factors

  • No material risk-factor changes disclosed versus the December 31, 2025 10-K
  • Litigation risk: SentreHEART complaint seeks up to $260,000 plus interest for alleged failure to pursue FDA approval
  • Operational risk: expansion lease commenced, adding $29,622 of finance lease liabilities
  • Financial risk: $61,000 ABL borrowings mature in 2029, with $62,750 unused capacity
  • Market risk: international revenue totaled $79,461 through nine months, exposing results to foreign currency fluctuations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other AtriCure, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.